342 related articles for article (PubMed ID: 29278737)
21. Ushering in the next generation of precision trials for pediatric cancer.
DuBois SG; Corson LB; Stegmaier K; Janeway KA
Science; 2019 Mar; 363(6432):1175-1181. PubMed ID: 30872517
[TBL] [Abstract][Full Text] [Related]
22. Blueprint for cancer research: Critical gaps and opportunities.
Elmore LW; Greer SF; Daniels EC; Saxe CC; Melner MH; Krawiec GM; Cance WG; Phelps WC
CA Cancer J Clin; 2021 Mar; 71(2):107-139. PubMed ID: 33326126
[TBL] [Abstract][Full Text] [Related]
23. One mouse, one patient paradigm: New avatars of personalized cancer therapy.
Malaney P; Nicosia SV; Davé V
Cancer Lett; 2014 Mar; 344(1):1-12. PubMed ID: 24157811
[TBL] [Abstract][Full Text] [Related]
24. Patient-specific multi-omics models and the application in personalized combination therapy.
John A; Qin B; Kalari KR; Wang L; Yu J
Future Oncol; 2020 Aug; 16(23):1737-1750. PubMed ID: 32462937
[TBL] [Abstract][Full Text] [Related]
25. Reasons to be testing: the dawn of complex molecular profiling in routine oncology practice.
Beer PA; Cooke SL; Chang DK; Biankin AV
Ann Oncol; 2019 Nov; 30(11):1691-1694. PubMed ID: 31665210
[No Abstract] [Full Text] [Related]
26. Ethical considerations of neuro-oncology trial design in the era of precision medicine.
Gupta S; Smith TR; Broekman ML
J Neurooncol; 2017 Aug; 134(1):1-7. PubMed ID: 28555425
[TBL] [Abstract][Full Text] [Related]
27. Application of molecular profiling in clinical trials for advanced metastatic cancers.
Kummar S; Williams PM; Lih CJ; Polley EC; Chen AP; Rubinstein LV; Zhao Y; Simon RM; Conley BA; Doroshow JH
J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25663694
[TBL] [Abstract][Full Text] [Related]
28. Omics-Based Strategies in Precision Medicine: Toward a Paradigm Shift in Inborn Errors of Metabolism Investigations.
Tebani A; Afonso C; Marret S; Bekri S
Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27649151
[TBL] [Abstract][Full Text] [Related]
29. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
Albin N; Mc Leer A; Sakhri L
Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
[TBL] [Abstract][Full Text] [Related]
30. An integrated framework for reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic sequencing data in support of clinical trials in personalized medicine.
Nasser S; Kurdolgu AA; Izatt T; Aldrich J; Russell ML; Christoforides A; Tembe W; Keifer JA; Corneveaux JJ; Byron SA; Forman KM; Zuccaro C; Keats JJ; Lorusso PM; Carpten JD; Trent JM; Craig DW
Pac Symp Biocomput; 2015; ():56-67. PubMed ID: 25592568
[TBL] [Abstract][Full Text] [Related]
31. Precision oncology based on omics data: The NCT Heidelberg experience.
Horak P; Klink B; Heining C; Gröschel S; Hutter B; Fröhlich M; Uhrig S; Hübschmann D; Schlesner M; Eils R; Richter D; Pfütze K; Geörg C; Meißburger B; Wolf S; Schulz A; Penzel R; Herpel E; Kirchner M; Lier A; Endris V; Singer S; Schirmacher P; Weichert W; Stenzinger A; Schlenk RF; Schröck E; Brors B; von Kalle C; Glimm H; Fröhling S
Int J Cancer; 2017 Sep; 141(5):877-886. PubMed ID: 28597939
[TBL] [Abstract][Full Text] [Related]
32. Art and Challenges of Precision Medicine: Interpreting and Integrating Genomic Data Into Clinical Practice.
Madhavan S; Subramaniam S; Brown TD; Chen JL
Am Soc Clin Oncol Educ Book; 2018 May; 38():546-553. PubMed ID: 30231369
[TBL] [Abstract][Full Text] [Related]
33. Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine.
Tian Q; Price ND; Hood L
J Intern Med; 2012 Feb; 271(2):111-21. PubMed ID: 22142401
[TBL] [Abstract][Full Text] [Related]
34. Precision Oncology: Between Vaguely Right and Precisely Wrong.
Brock A; Huang S
Cancer Res; 2017 Dec; 77(23):6473-6479. PubMed ID: 29162615
[TBL] [Abstract][Full Text] [Related]
35. Targeted therapy in cancer.
Tsimberidou AM
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1113-32. PubMed ID: 26391154
[TBL] [Abstract][Full Text] [Related]
36. The evolving potential of companion diagnostics.
Khoury JD
Scand J Clin Lab Invest Suppl; 2016; 245():S22-5. PubMed ID: 27433788
[TBL] [Abstract][Full Text] [Related]
37. Practice innovation: the need for nimble data platforms to implement precision oncology care.
Elfiky A; Zhang D; Krishnan Nair HK
Discov Med; 2015; 20(108):27-32. PubMed ID: 26321084
[TBL] [Abstract][Full Text] [Related]
38. [Precision medicine from experimental to clinical applications in oncology].
Normanno N
Recenti Prog Med; 2015 Dec; 106(12):597-600. PubMed ID: 26780068
[TBL] [Abstract][Full Text] [Related]
39. Lectin-based biosensors as analytical tools for clinical oncology.
Silva MLS
Cancer Lett; 2018 Nov; 436():63-74. PubMed ID: 30125611
[TBL] [Abstract][Full Text] [Related]
40. Future Clinical Trials: Genetically Driven Trials.
Astsaturov I
Surg Oncol Clin N Am; 2017 Oct; 26(4):791-797. PubMed ID: 28923231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
